title: Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective.
abstract: Until recently there have been few primary care office-based strategies to reduce the transmission of HIV. In May 2014 the Centers for Disease Control and Prevention published updated practice guidelines recommending the use of preexposure prophylaxis (PrEP) with daily oral dosing of tenofovir/emtricitabine to help prevent HIV infection in high-risk individuals (strength of recommendation, A). Knowledge of PrEP among primary care providers is low, however, and this intervention is likely reaching only a small fraction of eligible patients. PrEP is recommended for certain injection drug users, nonmonogamous men who have sex with men, heterosexual women who have sex with men who have sex with men or injection drug users, and those in HIV serodiscordant relationships. Providers should obtain baseline laboratory values and provide initial counseling before prescribing PrEP. Regular office visits are necessary to ensure adherence, provide ongoing counseling, and monitor for side effects, including nausea, abdominal pain, headache, and, less commonly, increased creatinine. Guidelines and toolkits have been developed to assist in incorporating PrEP into primary care practice. PrEP is gaining widespread acceptance and has become a crucial tool in the fight to stop the spread of HIV.
authors.affiliation: From the Department of Family Medicine and Community Health, University of Wisconsin-Madison, Madison. james.conniff@fammed.wisc.edu.
authors.forename: James
authors.initials: J
authors.lastname: Conniff
authors.affiliation: From the Department of Family Medicine and Community Health, University of Wisconsin-Madison, Madison.
authors.forename: Ann
authors.initials: A
authors.lastname: Evensen
mesh_terms: D000284:Administration, Oral; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D018890:Chemoprevention / Q000191:economics / Q000379:methods / Q000592:standards; D003362:Cost-Benefit Analysis; D004338:Drug Combinations; D000068679:Emtricitabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D055118:Medication Adherence / Q000523:psychology*; D062405:Motivational Interviewing; D017410:Practice Guidelines as Topic; D011320:Primary Health Care / Q000191:economics / Q000379:methods / Q000592:standards*; D018570:Risk Assessment; D012747:Sexual Partners; D015819:Substance Abuse, Intravenous; D000068698:Tenofovir / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D047568:Unsafe Sex / Q000517:prevention & control
chemical_list: D019380:Anti-HIV Agents; D004338:Drug Combinations; D000068698:Tenofovir; D000068679:Emtricitabine
keywords: Communicable Diseases; HIV; Infectious Diseases; Pharmacotherapy; Prevention & Control; Primary Health Care